Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1841 to 1850 of 2586 total matches.
Colon Cleansing
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.
In Brief: Prevention of Stroke in Patients with Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jun 01, 2009 (Issue 1313)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Atrial fibrillation increases the risk of stroke by a factor of 5. A randomized controlled trial (ACTIVE W) in 6706 patients with atrial fibrillation and one or more additional risk factors (≥75 years old; hypertension; previous stroke, transient ischemic attack or non- CNS embolus; left ventricular ejection fraction <45%; peripheral vascular disease; or 55-74 years old plus diabetes or coronary artery disease) found that a vitamin K antagonist such as warfarin (Coumadin, and others) was superior to clopidogrel (Plavix) plus aspirin in preventing vascular events, especially ischemic...
Vasopressors and Inotropes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011 (Issue 1377)
The Medical Letter®
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
The main purpose of vasopressors is to raise arterial
blood pressure, while that of inotropes is to increase
cardiac contractility. The choice of drugs is dictated by
the clinical setting. Controlled trials comparing the efficacy
and safety of these drugs are generally lacking.
Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
of therapy, including a proteasome inhibitor,
an immunomodulatory drug, and an anti-CD38
monoclonal ...
The FDA has approved ciltacabtagene autoleucel
(Carvykti – Janssen), a B-cell maturation antigen
(BCMA)-directed genetically-modified cellular product,
for treatment of relapsed or refractory
multiple myeloma in adults who received ≥4 prior
lines of therapy, including a proteasome inhibitor,
an immunomodulatory drug, and an anti-CD38
monoclonal antibody. Carvykti is an individualized
cellular product prepared from the patient's own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. Idecabtagene...
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
The Medical Letter®
on Drugs and Therapeutics
Volume 58 (Issue 1493) April 25, 2016
Take CME ...
The FDA has approved cariprazine (Vraylar – Actavis), an
oral, once-daily, second-generation antipsychotic, for treatment
of schizophrenia and for acute treatment of manic or
mixed episodes associated with bipolar I disorder.
Cefmetazole Sodium (Zefazone)
The Medical Letter on Drugs and Therapeutics • Jul 13, 1990 (Issue 822)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Cefmetazole sodium (Zefazone - Upjohn), a second-generation parenteral cephalosporin, was recently marketed in the USA for intravenous (IV) treatment of various infections caused by susceptible organisms. Like cefotetan (Cefotan), cefamandole (Mandol), cefoperazone (Cefobid), and moxalactam (Moxam), cefmetazole contains a methylthiotetrazole group that has been associated with prothrombin deficiency.
Trimethoprim-Polymyxin B for Bacterial Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990 (Issue 823)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Bacterial infections of the conjunctivae are usually self-limited, but topical antimicrobial therapy can be helpful. A solution of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000 units/ml (Polytrim - Burroughs Wellcome, distributed by Allergan) was recently marketed in the USA for treatment of superficial ocular bacterial infections.
Calcipotriene for Psoriasis
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994 (Issue 928)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration (FDA) for treatment of moderate plaque psoriasis, the most common form of the disease.
Thalidomide
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998 (Issue 1038)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications.
A New Conjugated Estrogen
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999 (Issue 1058)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen deficiency.